Ten questions skeptics often ask PMI

Philip Morris International (PMI) has delivered a company-wide transformation. We have committed energy, money, and resources to build our future on smoke-free products. Science, innovation, and technology have allowed for the development of new categories of tobacco and nicotine products that do not involve combustion, and therefore, smoke. 

In an ideal world, all smokers would quit tobacco and nicotine altogether. But we do not live in an ideal world. One billion people still smoke, and based on current trends this figure is not expected to change in the near future. Our ambition is to convince all adult smokers who would otherwise continue smoking cigarettes to switch to scientifically substantiated smoke-free products as soon as possible. Our vision is that these products will one day replace cigarettes. 

Since announcing our transformation in 2016, this vision has been the subject of criticism by some, who have expressed skepticism about our commitment and progress. We understand the tobacco industry faces a trust deficit. But we are not asking for trust. We are asking everyone to be part of the discussion on what society should do next. 

Our Chief Communication Officer, Dr. Moira Gilchrist, has responded to 10 skeptical questions about PMI’s transformation posed by Emeritus Professor Simon Chapman, an Australian tobacco control activist. Although Moira has offered to meet Professor Chapman to discuss his questions, he has so far declined to talk to her.

You say you want smokers to switch to IQOS or quit, yet Philip Morris USA refers to cigarettes as their “core product” on their website. Are cigarettes also PMI’s “core product” if cigarettes contribute to the biggest percentage of your income?

Philip Morris USA is a separate company from Philip Morris International. Philip Morris USA is owned by Altria and is neither an affiliate of PMI nor part of the same corporate organization. In 2025 Q1, approximately 42 percent of PMI’s total net revenue came from our smoke-free business, driven primarily by IQOS.¹ This area of our business, in line with our goals, continues to grow. We aim to make over two-thirds of our net revenues from smoke-free products by 2030. We are transforming our business away from cigarettes to smoke-free alternatives as quickly as possible. But we do not control the speed at which this happens on our own: Governments, regulators, scientists, and tobacco control activists all play a role. We encourage everyone to engage in a debate on how to bring solutions to men and women who don’t quit smoking in as short a time frame as possible. 

The largest chunk of PMI’s income is from its traditional tobacco products. Are sales and marketing employees in this section of the company still trying to increase sales?

We have transformed and are fully committed to our smoke-free vision. Our efforts are to get people who would otherwise continue smoking to switch to less harmful alternatives. Today, the majority of our business is still represented by cigarettes, but our goal is to replace those with reduced-risk products as fast as possible. As of March 31, 2025, we have launched smoke-free products in 95 markets worldwide.¹ In some countries, such as Australia, we are unable to launch them due to regulations banning or severely restricting their sales. In those countries, men and women who don’t quit cigarettes are being denied the opportunity to switch to better alternatives.

In the past, your company has opposed tobacco control policies, such as plain packaging, raising taxes on tobacco, and graphic health warnings. What do you say to critics who bring up these actions as conflicting with your new smoke-free direction?

The risks of smoking are well-known, and there’s absolutely no doubt that tobacco products should be subject—as they are—to strict rules and enforcement. In the past, we have opposed regulatory measures that we felt to be extreme and not backed by evidence of effectiveness. We agree that regulations should continue to dissuade people from starting to smoke or use nicotine-containing products, and also encourage people to quit. At the same time, it is equally clear that millions will continue to smoke—those people should have the opportunity to switch to better alternatives. The combination of sensible, risk-based regulation of smoke-free products, along with further restrictions on cigarettes, can be a more effective and faster method of reducing the harm caused by smoking than focusing only on typical regulatory measures.

Some critics claim PMI’s business model is focused on smoking AND vaping, not smoking OR vaping—how do you respond to this?

Clearly, a smoker’s best choice is to quit tobacco and nicotine altogether. But for those adults who would otherwise continue to smoke, switching completely to a scientifically substantiated smoke-free alternative is a better choice than continuing to smoke. We do not encourage dual use. We encourage adult smokers to switch completely to our smoke-free alternatives—abandoning cigarettes permanently—in order to obtain the full benefits compared to smoking.² As of December 31, 2024, we estimate that 32.2 million men and women are using our leading heated tobacco product, or whom 72 percent have switched completely and stopped smoking, and we would like to see that proportion grow.³

Would you also hope that children would not take up vaping? If you believe e-cigarettes are of “minimal risk,” why not openly encourage young people to vape?

Our message on this is very clear: we don’t want anyone—especially minors—to take up smoking cigarettes or using smoke-free products, and we do not encourage anyone to do so. Our smoke-free products are not risk-free, and they are addictive. They are only for adults who would otherwise continue to smoke or use nicotine products.

As fewer young people are taking up smoking compared to previous generations, doesn’t that mean looking far into the future that there will be fewer smokers available as potential IQOS customers?

We recognize the significant role the World Health Organization (WHO) are playing in driving policy to reduce smoking around the world. Yet despite these efforts, millions of people who understand the risks continue to smoke cigarettes. Data collected by the WHO show that annually on average only 2.5 percent of smokers quit, which means that the vast majority of smokers will continue to smoke. 

It is these hundreds of millions of men and women who stand to gain the most from less harmful alternatives to smoking. If those adults who would otherwise continue to smoke instead abandon cigarettes and switch to less harmful alternatives, the decline in smoking prevalence can significantly exceed the predicted rates of cessation.

Many stakeholders have voiced their concerns about the impact of youth initiation of e-cigarette products. We share this concern. The positive impact that smoke-free products can have for adult smokers who don't quit should not be thwarted by an increase in youth use of nicotine-containing products. Our Marketing Codes are strong and enforced globally. Multiple studies show that youth initiation of IQOS is low. We remain continually vigilant and welcome constructive feedback.

Altria, the parent company of Philip Morris USA, invested USD 12.8 billion in a vaping product that has been widely linked to a growing percentage of U.S. teenagers using e-cigarettes. Are you going to tell me that this teen use of e-cigs “concerns” you or that PMI was encouraged by those statistics?

Philip Morris USA is a separate company from Philip Morris International. Philip Morris USA is owned by Altria and is neither an affiliate of Philip Morris International nor part of the same corporate organization. We don’t want anyone—especially minors—to start smoking cigarettes or using smoke-free products, and we do not encourage anyone to do so. Our smoke-free alternatives are only for adults who would otherwise continue to smoke or use nicotine products.

Although smoke-free products appear to be less harmful than smoking cigarettes, they still contain nicotine, which is very addictive. Are you concerned that nicotine delivered through vaping could be very addictive?

Smoke-free products do not address concerns about addiction. The best option is never to start using tobacco or nicotine products. Those who have already started should quit. But if they would otherwise continue to smoke, they should switch to a scientifically substantiated smoke-free alternative. These products contain nicotine, which is addictive and not risk-free, but it is not the primary cause of smoking-related diseases. It is the combustion of tobacco that produces the vast majority of the harmful chemicals that are linked to smoking-related diseases. Smoke-free tobacco products, such as heated tobacco, e-vapor, and oral smokeless products, aim to reduce the harmful effects caused by smoking by eliminating the combustion of tobacco. 

In order for smoke-free products to be acceptable and effective less-harmful substitutes for cigarettes, it is important that a level of nicotine is present. Our clinical studies in adult smokers showed that those who switched to our heated tobacco product, IQOS, achieved comparable levels of nicotine uptake as those who continued to smoke their usual cigarettes. Importantly, nicotine exposure did not increase above levels observed at baseline, nor did it exceed the exposure levels in those who continued to smoke their usual cigarettes.⁴

Many companies expect their employees to use their products. Why do you think PMI is comfortable with having employees who choose not to smoke or vape?

Our position is clear. The best choice is never to start using nicotine and tobacco products. We embrace all kinds of talented people, whether they are smokers or not. We do not recruit people based on their smoking or vaping habits, and we do not encourage employees to smoke or use smoke-free products. In line with our company’s transformation and smoke-free vision, we are encouraging people from all over the world who do smoke—including our employees—to quit smoking or, if they choose not to, to switch to less harmful alternatives compared to smoking.

¹ PMI 2025 Q1 Results.

² Good conversion practices for PMI's smoke-free products.

³ PMI 2024 Q4 and Year-End Results.

⁴ PMI presentation to US FDA Tobacco Products Scientific Advisory Committee, Jan 24, 2018, slide 35.